| Literature DB >> 23810283 |
Noriyoshi Iriyama1, Yoshihiro Hatta, Jin Takeuchi, Yoshiaki Ogawa, Shigeki Ohtake, Toru Sakura, Kinuko Mitani, Fumihiro Ishida, Masatomo Takahashi, Tomoya Maeda, Tohru Izumi, Hisashi Sakamaki, Shuichi Miyawaki, Sumihisa Honda, Yasushi Miyazaki, Tomohiko Taki, Masafumi Taniwaki, Tomoki Naoe.
Abstract
We investigated the significance of surface antigen expression for prognosis by focusing on a specific subtype, AML with t(8;21). The investigation included 144 patients with AML with t(8;21) in the JALSG AML97 study. AML with t(8;21) expressed CD19 (36%), CD34 (96%), and CD56 (65%) more frequently than did other subtypes of AML. CD19 expression had a significant favorable effect on CR (95.7% vs. 83.8%; P=0.049). Univariate analysis showed that increased white blood cell (WBC) counts (WBC ≥ 20 × 10(9)/L), CD19 negativity, and CD56 positivity were critical adverse factors for relapse after CR; multivariate analysis revealed that WBC count and CD56 expression were independent adverse risk factors (HR 2.18; P=0.045, HR 2.30; P=0.011, respectively). We concluded that CD56 expression has a possible role in risk stratification for patients with AML with t(8;21).Entities:
Keywords: Acute myeloid leukemia with t(8 ;21); CD56 antigen; Prognostic factor
Mesh：
Substances：
Year: 2013 PMID： 23810283 DOI： 10.1016/j.leukres.2013.05.002
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156